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Abstract
 
Mast cells reside in tissues, where upon activation through the high-affinity-IgE-receptor
(Fc
 
 
 
RI) they degranulate and orchestrate the allergic reaction. Mast cells survive this activation
and can thus be reactivated. In this study we demonstrate that this process depends on the pro-
survival gene A1. Activation of mast cells through Fc
 
 
 
RI resulted in degranulation, strong in-
duction of A1 mRNA and protein, and cell survival. In contrast, A1-deficient mast cells
released granule mediators similar to the wild-type control, but the cells did not survive an al-
lergic activation. Furthermore, A1
 
 
 
/
 
 
 
 mice that had been sensitized and provocated with aller-
gen exhibited a lower number of mast cell compared with littermate controls. The induction of A1
was dependent on calcium, as EDTA prevented A1 expression. The calcium ionophore, iono-
mycin, induced A1 expression and mast cell survival, whereas compound 48/80, a well-known
mast cell secretagogue, did not. This study uncovers the importance of A1 for mast cell survival
in allergic reactions, and it proposes A1 as a potential target for the treatment of allergic diseases.
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Introduction
 
Mast cells are central effector and regulatory cells in allergic
diseases. They are long-lived cells that are widely distrib-
uted throughout vascularized tissues and certain epithelia,
where they play a fundamental role in the pathogenesis of
immediate hypersensitivity reactions (1–3). Especially in
diseases such as allergy and asthma, an increased number of
tissue mast cells can be documented (2), and a correlation
between the number of mast cells in the tissue and the se-
verity of the symptoms has been described (4–7). In allergy,
multivalent antigens bind and cross-link IgE molecules
bound to the high-affinity IgE-receptor (Fc
 
 
 
RI)
 
*
 
 expressed
on mast cells (8). Receptor aggregation induces multiple
signaling pathways that control diverse cellular functions
(9). One of the key events induced by cross-linking of
Fc
 
 
 
RI is the rapid release of a broad spectrum of vasoactive
and proinflammatory mediators causing the symptoms asso-
ciated with an allergic reaction (1, 3, 10). Thus, mast cell
activation and hyperplasia are key components that con-
tribute to allergic diseases.
A unique feature of mast cells is that they withstand the
exhaustive degranulation process, survive, regranulate, and
can thereafter be activated again (11, 12). Therefore, a fun-
damental question in mast cell biology is how the cells sur-
vive the Fc
 
 
 
RI-mediated degranulation process, which is
an important feature of these cells for the perpetuation of
an allergic reaction.
One important mechanism for protecting cells from
apoptosis is through the regulation of a number of proto-
oncogenes whose products interact to determine the final
outcome of apoptotic signals. A major class of such intra-
cellular regulators is the bcl-2 family of proteins (13). The
bcl-2 family includes a number of apoptosis-regulatory
genes, which may either be death antagonists (bcl-2,
 
bcl-X
 
L
 
, bcl-w, mcl-1, and A1/bfl1) or death agonists
(bax, bak, bcl-X
 
S
 
, bad, bid, and bik) (14, 15). Although the
precise mechanism by which bcl-2 family members influ-
ence apoptosis is unknown, several lines of evidence sug-
gest that bcl-2 proteins function at a critical decision point
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NGF, nerve growth factor; RPA, ribonuclease protection assay; SCF,
stem cell factor. 
1562
 
A1 Expression in Mast Cells
 
immediate upstream of an irreversible commitment to cell
death (16).
The role of survival/apoptosis-regulatory genes in mast
cell activation has not been fully defined. There are some
reports on the expression and regulation of bcl-2 in mast
cells (17–20). Despite the wide-ranging ability of bcl-2 to
promote cell survival, it is clear that in a number of circum-
stances bcl-2 is not responsible for protecting cells from
apoptosis (21, 22). Therefore, it is possible that other mem-
bers of the bcl-2 family may provide protective effects in
some specific biological processes.
One of the pro-survival bcl-2 homologues is A1, which
was originally identified from mouse bone marrow culture
induced with GM-CSF (23). A1 was described as an early-
response gene, expressed in multiple tissues such as thymus,
spleen, and bone marrow, and also expressed in a number
of hemotopoietic cell lineages including T- and B lympho-
cytes, macrophages, neutrophils, and endothelial cells (23–
26). A1 is the only bcl-2 family member that is inducible
by inflammatory cytokines such as TNF-
 
 
 
 and IL-1
 
 
 
,
which suggests a possible role for A1 in inflammatory re-
sponses (27). The present study addresses the question of a
possible role for bcl-2 family genes in the regulation of
mast cell survival after activation by Fc
 
 
 
RI cross-linking.
Our results demonstrate a critical role for A1 in mast cell
survival upon allergic activation.
 
Materials and Methods
 
Mast Cell Culture.
 
Bone marrow–derived cultured mouse
mast cells (BMCMCs) were obtained by culturing mouse bone
marrow cells from C57BL/6 and BALB/c (Bommice). BM-
CMCs were also obtained from mice lacking A1-a (C57BL/6
genetic background) (28), one of the A1 subtypes (29). Bone
marrow cells were cultured in 10% WEHI-3 enriched condi-
tioned RPMI 1640, supplemented with 10% heat-inactivated fe-
tal bovine serum, 4 mM L-glutamine, 50 
 
 
 
M 2-mercaptoetha-
nol, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids,
10 mM Hepes, and 100 
 
 
 
g/ml penicillin/streptomycin (Sigma-
Aldrich). Mast cell development was confirmed by toluidine blue
staining and the expression of Kit on the cell surface. The growth
factor–dependent mouse mast cell lines MCP5/L (30) (obtained
from Dr. D.D. Metcalfe, National Institutes of Health, Bethesda,
MD) and MC/9 (American Type Culture Collection) were
maintained in the same medium as described above. The
growth-factor independent cell line C57 (31, 32) (obtained from
Dr. S.J. Galli, Stanford University, Stanford, CA) were main-
tained in RPMI medium supplemented with 10% FCS and 50
 
 
 
M 2-mercaptoethanol.
 
Cell Survival Assay.
 
For cell viability assays, the cell suspen-
sion was mixed with the vital dye, trypan blue, and the number
of live cells was enumerated. Cell apoptosis was measured by
Cell Death Detection ELISA (Boehringer), quantitatively de-
tecting the mono- and oligo-nucleosomes released into culture
supernatant.
 
Mast Cell Activation.
 
For Fc
 
 
 
RI-dependent activation, mast
cells were sensitized using a monoclonal murine IgE anti-TNP
antibody (IgEl-b4; American Type Culture Collection; used as
15% hybridoma supernatant) for 90 min. After two washings, the
cells were subjected to challenge with 1 
 
 
 
g/ml TNP-BSA (cou-
pling ratio: 4.8, provided by Dr. Birgitta Heyman, Uppsala Uni-
versity) for time periods as indicated. For cell viability and 
 
 
 
-hex-
osaminidase release assays, both the antibody sensitization and the
antigen challenge were performed in RPMI supplemented with
0.5% BSA at 37
 
 
 
C. For gene regulation studies, all the incuba-
tions were carried out in RPMI supplemented with 5% FCS or as
indicated in the text. To determine the effects of ionomycin or
compound 48/80 (Sigma-Aldrich) on A1 regulation, cells were
resuspended in medium containing ionomycin or compound 48/
80 and incubated for 6 h at 37
 
 
 
C. For detection of 
 
 
 
-hex-
osaminidase, an enzymatic colorimetric assay was used as de-
scribed (33). In brief, supernatant or cell lysate was mixed with an
identical volume of substrate solution (7.5 mM p-nitrophenyl
N-acetyl-
 
 
 
-D-glucosaminide (Sigma-Aldrich) in 80 mM citric
acid, pH 4.5) and incubated at 37
 
 
 
C for 2 h. The reaction was
stopped by the addition of glycine (0.2 M, pH 10.7) into each
well and the absorbance was measured. For inhibition studies,
cells were cross-linked in medium containing EDTA (1 mM),
wortmannin (100 nM), dexamethasone (1 
 
 
 
M), or cyclohexi-
mide (10 
 
 
 
g/ml; Sigma-Aldrich). EDTA was added at the same
time as the addition of IgE. Dexamethasone was added 14 to 16 h
before IgE sensitization. The other inhibitors were added at the
same time as Fc
 
 
 
RI aggregation. In some experiments, mast cells
were treated with cytokines which include rmTNF-
 
 
 
 (10 ng/ml),
rm GM-CSF (10 ng/ml), rm stem cell factor (SCF; 100 ng/ml),
rmIL-4 (10 ng/ml; PeproTech), and mouse nerve growth factor
(NGF; 100 ng/ml; Promega), for 1, 3, 6, and 18 h.
 
Ribonuclease Protection Assay.
 
Total cellular RNA was isolated
using the TriPure isolation reagent (Boehringer). Ribonuclease
protection assay (RPA) was performed using the mAPO-2 multi-
probe set from the RiboQuant System (BD PharMingen) follow-
ing the supplier’s recommended protocol. Quantification of
mRNA expression was determined using a PhosphorImaging de-
vice, and levels of each gene transcript were quantified by
MacBas V2.2 (Fuji Photo Film Co. Ltd.).
 
Western Blot.
 
BMCMCs were activated in complete medium
through Fc
 
 
 
RI cross-linking and cells were harvested at 6, 12, 18,
30, 48, and 72 h postactivation, washed once in PBS, and lysed
in hot 2
 
 
 
 SDS gel sample buffer (20 mM dithiothreitol, 6%
SDS, 0.25 M Tris, pH 6.8, 10% glycerol, and bromophenyl
blue). The protein concentration in the samples was measured us-
ing a Bradford assay (Bio-Rad Laboratories) and 50 
 
 
 
g of protein
was resolved on SDS-10% polyacrylamide gels. Protein was then
electroblotted to nitrocellulose membrane. Equal protein loading
was confirmed by Ponceau S (Sigma-Aldrich) staining of the gel
after transfer. A1 protein was detected using a rat monoclonal an-
tiserum against murine A1 (R&D Systems) and bcl-X
 
L
 
 was de-
tected using a rabbit anti-bcl-X
 
L
 
 (Santa Cruz Biotechnology,
Inc.), followed by a horseradish peroxidase–conjugated sheep
anti–rat or goat anti–rabbit antibody (Amersham Pharmacia Bio-
tech) at a 1:2,000 dilution. Western blots were then visualized by
chemoluminescence using enhanced chemoluminescence (ECL).
 
Immunization and Histochemical Staining.
 
Female A1-a knock-
out and littermate control mice (three mice/group) between 8
and 12 wk of age, which were maintained on OVA-free diet,
were used. Immunization was conducted weekly for 4 wk by in-
jections of 20 
 
 
 
g intraperitoneally chicken OVA (grade V;
Sigma-Aldrich) adsorbed to 1 mg alum in 0.2 ml PBS. 2 d after
the last exposure the mice were provocated with an identical
dose of OVA plus alum intraperitoneally. 2 d later skin samples
were collected from the footpad.
Skin biopsies from the footpad were fixed in 4% paraformalde-
hyde overnight and embedded in paraffin blocks. Skin sections 
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were cut (5 
 
 
 
m) and mounted on Superfrost
 
® 
 
Plus slides. After
deparaffinization steps the sections were stained with toluidine
blue for 10 min. Mast cell number was assessed in three skin sec-
tions for each animal. Quantification was performed in coded
slides in three randomly selected areas of each section.
 
Statistics.
 
Statistics were calculated using an analysis of vari-
ance (ANOVA), followed by multiple comparison using Fisher’s
method. 
 
*
 
 denotes 
 
P
 
 
 
 
 
 0.05, 
 
**
 
 
 
P 
 
 
 
 0.01. Values presented are
the means 
 
  
 
SEM.
 
Results
 
Cross-linking of Fc
 
 
 
RI Prevents Apoptosis Induced by Growth
Factor Deprivation.
 
IL-3 is one of the primary growth fac-
tors for murine mast cells. Both mouse mast cell line
MCP5/L and BMCMCs are growth factor dependent, and
they require the inclusion of IL-3 in their media for sur-
vival. As shown in Fig. 1, A and B, withdrawal of WEHI,
which forms the source of IL-3, resulted in a progressive
decrease in the number of live cells as determined by try-
pan blue exclusion staining. To examine whether mast cell
activation would influence the survival of cells deprived of
growth factor, we activated MCP5/L cells and BMCMCs
through Fc
 
 
 
RI aggregation. The survival percentage of ac-
tivated MCP5/L increased compared with control cells af-
ter 2 d of incubation, and on days 4 and 5 Fc
 
 
 
RI aggrega-
tion led to cell survival promotion by 
 
 
 
70 and 120%,
respectively, over control cells (Fig. 1 A). For BMCMCs,
which are more sensitive to growth factor withdrawal,
Fc
 
 
 
RI aggregation resulted in cell survival promotion by
74 and 600% on the second and third day, respectively
(Fig. 1 B).
One distinct feature indicating apoptosis is the activation
of an endogenous endonuclease which cleaves double-
stranded DNA at the most accessible internucleosomal
linker region, generating mono- and oligo-nucleosomes.
By measuring the release of mono- and oligo-nucleosomes,
we could confirm that cross-linking of Fc
 
 
 
RI rescued the
cells from undergoing apoptosis (Fig. 1 C). Thus, the acti-
vation of mast cells through Fc
 
 
 
RI initiates a cellular re-
sponse that directly prevents apoptosis, without the addi-
tion of exogenous growth factors.
 
A1 Is Upregulated upon Fc
 
 
 
RI Activation.
 
Apoptosis is
regulated by members of the bcl-2 family that can either
be prosurvival or proapoptotic. Our finding that cross-
linking of Fc
 
 
 
RI promotes mast cell survival upon growth
factor withdrawal, led us to investigate whether this activa-
tion induced transcriptional regulation of any of the bcl-2
family members.
RPA was performed on MCP5/L cells either at resting
condition or after activation by Fc
 
 
 
RI, using the mAPO-2
multi-probe set from BD PharMingen which allows the si-
multaneous analysis of multiple bcl-2 family genes. What
attracted our initial attention was a striking up-regulation
of the pro-survival bcl-2 homologue A1 (Fig. 2 A). A1 was
absent in resting cells but substantially upregulated after
Fc
 
 
 
RI aggregation for 6 h. For the other genes analyzed,
no obvious regulation was observed directly from the
PhosphorImaging picture. Therefore we quantified the
bands by densitometric analysis (Fig. 2 B). The A1 mRNA
level in cells activated by Fc
 
 
 
RI aggregation had increased
 
 
 
26-fold when the signal was compared with that of con-
trol cells (Fig. 2 B). Bcl-X
 
L
 
 was upregulated by an increase
of 1.8-fold over control cells. The identity of bcl-X
 
L
 
 was
confirmed by Western blot (data not shown). As for other
genes, Fc
 
 
 
RI aggregation did not modulate the regulation
of gene expression levels (Fig. 2 B). The expression of A1
in activated mast cells was confirmed in BMCMCs from
C57BL/6 and BALB/c mice, as well as in other mast cell
lines (MC/9 and C57; Fig. 2 C, and data not shown). We
also performed control experiments for the Fc
 
 
 
RI aggrega-
tion where either IgE-anti-TNP or the antigen was omit-
ted. 
 
 
 
-hexosaminidase release, promotion of mast cell sur-
Figure 1. Survival promotion after mast cell activation by Fc RI cross-
linking. MCP5/L cells (A) or BMCMCs from C57BL/6 (B and C) were
either stimulated through cross-linking of Fc RI (IgE CL) or left un-
treated in RPMI deprived of serum and growth factors. Viability was de-
termined by trypan blue exclusion and presented as the percentage of in-
put cells that are still alive when examined every 24 h (A and B). In C,
BMCMC apoptosis was assessed by ELISA measuring the release of nu-
cleosomes into the culture supernatant after 24 h. Data are presented as
the mean   SEM from three to five separate experiments. 
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vival, or A1 induction could not be determined in any of
these experiments (data not shown).
As the mast cell activation was performed in low-serum
and growth factor–deprived medium, which is not a physi-
ological condition we next investigated if A1 could be in-
duced also in the presence of serum with or without IL-3.
As shown in Fig. 2 C, A1 was indeed induced after Fc
 
 
 
RI
aggregation also in the presence of IL-3. Furthermore, C57
cells that are growth factor independent also exhibit A1 in-
duction upon activation further supporting that IL-3 is not
a prerequisite for the expression of A1 (Fig. 2 C).
We next investigated the kinetics of A1 expression in
mast cells upon Fc
 
 
 
RI cross-linking. Kinetic studies re-
vealed that A1 transcript could be detected 2 h after activa-
tion, peaked around 6 h, and was no longer detectable by
24 h (Fig. 3 A). A similar expression pattern has been ob-
served in macrophages and endothelial cells stimulated with
cytokines or LPS (23, 26).
To confirm the translation of A1 mRNA into protein af-
ter mast cell activation, we performed Western blotting to
measure the intracellular A1 protein expression. The results
indicated that A1 protein expression in BMCMCs was de-
tectable at 6 h and peaked at around 48 h after Fc
 
 
 
RI-
mediated activation (Fig. 3 B).
Under physiological conditions, mast cells do not die af-
ter degranulation triggered by Fc
 
 
 
RI aggregation, and pre-
viously activated mast cells can be activated again. If A1
plays a role in mast cell survival after activation, it would
be interesting to explore whether A1 expression is repeat-
edly induced in mast cells after repeated activation of
Fc
 
 
 
RI. MCP5/L cells were therefore first activated by IgE
and antigen, washed, and then activated again 48 h after
the initial activation. The kinetics demonstrated that A1
appeared 2 h after the second Fc
 
 
 
RI aggregation, peaked at
around 6 h, after which the expression declined (Fig. 3 C),
which is similar to the initial activation (Fig. 3 A). The re-
lease of the granule-associated 
 
 
 
-hexosaminidase was mea-
sured upon the second activation to indicate mast cell de-
granulation, which is also similar to the initial activation
(data not shown).
Thus, through cross-linking of Fc
 
 
 
RI mast cells can be
repeatedly activated to degranulate, and this process is ac-
companied by the repeated induction of A1 expression.
 
Regulation of A1 Expression.
 
In mast cell activation, the
sequence of events leading from receptor cross-linking to
exocytosis has been well elucidated, and one of the hall-
Figure 2. bcl-2 family gene expression in mast cells after cross-linking
of Fc RI. (A) RPA was performed to analyze the expression levels of the
indicated genes on total RNA isolated from MCP5/L cells either resting
or activated for 6 h through Fc RI cross-linking (IgE CL). Lane 1, resting
cells cultured in the presence of WEHI-3–conditioned medium. Lane 2,
resting cells that were incubated and washed through the same procedures
needed for Fc RI cross-linking (deprived of growth factor). Lane 3, cells
that were stimulated through Fc RI cross-linking. A representative ex-
periment of at least six performed independently is shown. (B) Phosphor-
Imaging signals presented in A (lanes 2 and 3) are shown as gene expres-
sion relative to the average expression of the house keeping genes
GAPDH and L32. Data are normalized such that the densitometric level
of each gene from the control cells is given a value of 1. (C) RPA was
performed as in A to analyze A1 induction in MCP5/L and C57 cells ac-
tivated for 6 h in the presence or absence of FCS and WEHI as a source
of IL-3.
Figure 3. Kinetics of A1 mRNA and protein expression in mast cells
activated by Fc RI cross-linking. (A) RPA was performed on RNA iso-
lated from MCP5/L cells either at resting state or activated through
Fc RI cross-linking (IgE CL) for various time points as indicated to de-
tect A1 transcript levels. (B) Accumulation of A1 protein in resting and
activated BMCMCs was analyzed by Western blot analysis. (C) MCP5/L
cells were activated through Fc RI cross-linking (1st CL) up to 24 h, and
then were washed and incubated under normal culture condition. 48 h
after the first activation, cellular IgE receptors were cross-linked again
(2nd CL). A1 induction at time points both in the first and the second ac-
tivation periods were analyzed by RPA. Data shown are representative of
three separate experiments. 
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marks of cellular activation is an increase in concentrations
of free intracellular calcium that is derived from both extra-
cellular and intracellular stores (9). Therefore we were in-
terested to reveal how A1 regulation would be affected
when mast cell activation was performed in the presence of
the Ca
 
2
 
 
 
 and Mg
 
2
 
 
 
 chelating agent EDTA. Our results
showed that neither the release of 
 
 
 
-hexosaminidase (data
not shown) nor the induction of A1 (Fig. 4) could be de-
tected in activated MCP5/L when EDTA was present.
To investigate the regulatory control of A1 expression in
more detail, we treated MCP5/L cells with dexametha-
sone, wortmannin, and cycloheximide. As shown in Fig. 4,
all inhibitors completely blocked A1 induction.
 
Ionomycin but Not Compound 48/80 Induces A1 Expression
and Mast Cell Survival.
 
To determine whether the regula-
tion of A1 transcript was only seen with Fc
 
 
 
RI aggregation
as a physiological stimulus, or if A1 induction could also be
achieved in response to other stimuli, MCP5/L cells were
exposed to ionomycin for 6 h. Ionomycin is a calcium ion-
ophore, which induces increased levels of intracellular cal-
cium, capable of mimicking the activation of Fc
 
 
 
RI. Simi-
lar to Fc RI aggregation, activation with ionomycin led to
induction of A1, release of  -hexosaminidase, and mast cell
survival in a dose-dependent manner (Fig. 5, A–C). Re-
lease of  -hexosaminidase after ionomycin treatment as
well as Fc RI aggregation of MCP5/L cells was 10–15%.
The conclusion from these data, as well as the fact that
EDTA could block A1 induction (Fig. 4), is that A1 is in-
duced through a calcium-dependent mechanism.
Another well-known mast cell secretagogue is com-
pound 48/80, which induces exocytosis without elevation
of cytosol Ca2  and activates G-proteins directly (34). Fur-
thermore, GTP-binding proteins are located downstream
of signal transduction pathways leading from receptor acti-
vation to exocytosis, so that the release of mast cell granules
can be triggered by direct activation of such proteins (35).
Prompted by these descriptions, we then explored whether
compound 48/80 would induce A1 expression in mast
cells. As shown in Fig. 5 D, compound 48/80 at concen-
trations of up to 100  g/ml failed to upregulate A1 induc-
tion, although it triggered a substantial release of  -hex-
osaminidase (Fig. 5 E). What is compatible with our
hypothesis that A1 is responsible for mast cell survival dur-
ing its degranulation process, is that the treatment of cells
with compound 48/80 failed to rescue cells from dying af-
ter growth factor deprivation (Fig. 5 F). These data support
the hypothesis that the difference in survival promotion
potential between ionomycin and compound 48/80 is re-
lated to A1 regulation.
Cytokines Fail to Induce A1 in Mast Cells. A1 was ini-
tially described as an early-response gene whose expres-
sion was associated with a variety of inflammatory stimuli
such as GM-CSF and TNF-  (23, 26). We therefore ana-
lyzed whether cytokines previously shown to induce A1
in other cell types had a similar effect on mast cells. In ad-
dition we tested IL-4, SCF, and NGF, which have been
implicated in regulating mast cell survival/apoptosis (18,
20, 36–38). As shown in Fig. 6, none of these cytokines
induced expression of A1 in growth factor–deprived mast
cells. We also analyzed the effect of IL-3 on A1 induction.
Both BMCMCs and MCP5/L are growth factor depen-
dent and were cultured in the presence of IL-3, although
the activation studies were performed in growth factor–
deprived medium. Culturing the cells in the presence of
IL-3 did not induce expression of A1 (Fig. 2 A, 1st lane),
and the presence of IL-3 during the activation did not af-
fect the induction of A1 (Fig. 2 C). Furthermore, treat-
ment of the growth factor–independent mast cell line C57
with IL-3 did not cause any induction of A1 (data not
shown).
Mast Cells Deficient in A1 Do Not Survive an Allergic Acti-
vation. To address the issue of whether A1 is a prerequi-
site for mast cell survival upon cross-linking of Fc RI, or if
Figure 4. Effects of a number of
inhibitors on A1 induction in mast
cells after activation by Fc RI cross-
linking. RPA was performed on
RNA from MCP5/L cells which
were activated through Fc RI cross-
linking (IgE CL) in the absence or
presence of various inhibitors as in-
dicated. Data shown represent com-
parable results from at least three
separate experiments.
Figure 5. The effects of ionomycin and compound 48/80 on mast cell
A1 expression, mediator release, and survival. RPA was performed on
RNA derived from MCP5/L cells incubated for 6 h in the presence of
ionomycin or compound 48/80 at concentrations indicated (A and D).
Release of  -hexosaminidase ( -hex) after 30 min was measured using an
enzymatic colorimetric method and was indicative of activation and de-
granulation of mast cells (B and E). Survival rate of mast cells after 4 days
in medium deprived of serum and growth factors was measured (C and F)
as explained in Fig. 1. Data shown in A and D are a representative of
three separate experiments and data shown in the rest are expressed as the
mean   SEM from three experiments.1566 A1 Expression in Mast Cells
the up-regulation of A1 is just a parallel phenomenon, we
used mast cells deficient in A1-a (28). A1-a /  mice are
healthy and fertile, but have an increased spontaneous
apoptosis of neutrophils (28). They have normal numbers
of mast cells in the skin, lung, and spleen (data not shown).
The A1-a /  BMCMCs had a morphology similar to wild-
type mast cells, stained with toluidine blue, expressed Kit
on the surface, and the cell growth rate was similar to the
wild-type control. Thus, A1 seems not to have any obvious
role in mast cell homeostasis or in vitro development. Upon
activation with IgE and antigen, the A1-a /  BMCMCs
released granule-associated  -hexosaminidase similar to the
wild-type control (Fig. 7 A). Cross-linking of Fc RI did
not promote survival of these cells; instead they died at a
similar rate as resting control cells (Fig. 7 B). Thus, this
finding confirms the hypothesis that A1 expression is nec-
essary for mast cell survival upon allergic activation.
We also examined the number of mast cells in vivo after
allergen provocation. Mice deficient in A1-a expressed the
same number of mast cells in the skin of the footpad as
wild-type control ( 5 mast cells/mm2). However, after al-
lergen challenge and provocation, a significant difference in
mast cell number could be observed in the skin of A1-a / 
compared with the littermate control mice (Fig. 7 C). The
mast cell number in the skin of A1-a /  was decreased by
 50% compared with A1-a / .
Discussion
The current study demonstrates that A1 is central to
Fc RI-induced mast cell survival, while not having any
obvious role in mast cell development. Mice deficient in
A1 expressed normal numbers of mast cells in the skin,
lung, and spleen. Furthermore, there was no difficulty cul-
turing mast cells from the bone marrow of A1-deficient
mice. However, A1 /  mast cells did not survive an aller-
gic activation by cross-linking of the high-affinity IgE-
receptor in vitro, and the mast cell number was reduced in
vivo in A1 /  mice after allergen sensitization and provo-
cation (Fig. 7).
One of many interesting features of mast cells is that
they, upon degranulation, can regranulate and be activated
again. In ultrastructural studies it has been shown that mast
cells, upon IgE-dependent activation, enter a stage mani-
fested by very dramatic exocytosis, including the release of
nearly all cell granules and the shedding of large amounts of
membranes, surface processes, and cytoplasmic fragments
(12, 39). One characteristic feature of the acute allergic re-
action is that it can be initiated repeatedly, for example
during a pollen season. This is most likely due to the de-
and regranulation capacity of mast cells. The involvement
of bcl-2 family members in regulating this process, al-
though logical, has hitherto been unconfirmed.
Several previous studies have indicated the possible role
of bcl-2 in mast cell biology. For instance, overexpression
of bcl-2 cDNA prolongs the survival of mast cells upon
withdrawal of IL-3 (40), and overexpression of bcl-2 by
human bone marrow mast cells is found in mast cell leuke-
Figure 6. Absence of A1 induction in cells treated with cytokines.
MCP5/L cells were incubated in the presence of various cytokines as
indicated for 6 h and A1 expression was measured by RPA. Cells that
were activated by Fc RI cross-linking (IgE CL) were presented as
positive control.
Figure 7. Absence of survival promotion of mast cells from A1 / 
mice after Fc RI cross-linking (IgE CL). (A)  -hexosaminidase ( -hex)
release from A1 /  mast cells was assessed as explained in Fig. 5 to dem-
onstrate that the cells were properly activated. (B) BMCMCs from A1
knockouts and wild-type littermates were stimulated and viability was de-
termined as explained in Fig. 1. (C) The mast cell number was quantified
in the footpad skin sections of A1-a /  and wild-type control mice before
and after OVA treatment as detailed in Materials and Methods. Values
presented are the means   SEM from three to six separate experiments.1567 Xiang et al.
mia (41). Bcl-2 is also induced upon treatment of mast cells
with IL-3 or NGF (17, 18). However, in our mast cell
Fc RI-dependent activation model, we have not found
any significant regulation of bcl-2 transcript levels (Fig. 2).
Although bcl-2 is the most extensively studied death antag-
onist and has been shown to enhance cell survival by inhib-
iting apoptosis under a wide variety of circumstances, bcl-
2–independent prevention of apoptosis has also been
reported (22). Therefore, it should not be surprising that
A1 but not bcl-2 is upregulated and promotes mast cell sur-
vival after IgE-dependent activation.
A pronounced upregulation, like an all-or-none event,
was seen in A1 (Fig. 2), which strongly suggests that A1
might play a key role in mast cell activation-dependent sur-
vival promotion and hence in the long life-span of mast
cells. A similar on/off effect has been shown for A1 expres-
sion after treatment of macrophages and endothelial cells
with inflammatory cytokines and LPS (23, 26, 42). A1 has
been demonstrated to exert a prominent role in the pre-
vention of apoptosis in a variety of cell systems. A1 pro-
longs cell survival during myeloid differentiation (42) and
protects endothelial cells from apoptosis induced either by
serum starvation (43) or by TNF-  treatment (26).
In addition to A1, we could detect an increase of bcl-XL
after Fc RI aggregation (Fig. 2). It has been shown that
activation of v-Abl protein tyrosine kinase in pre-mast
cells results in the suppression of apoptosis after with-
drawal of IL-3, and the activation is followed by an
approximately twofold increase at the mRNA level of
bcl-XL (44). Our observation of an approximately 1.8-fold
increase of bcl-XL (Fig. 2 B) is compatible with the above
finding, and suggests that bcl-XL might also be functional
in mast cell activation.
It is not clear from our results if the survival role of A1 in
mast cells is mediated through direct or indirect mecha-
nisms. Several studies have shown that members of the bcl-2
family can interact with each other and form dimers (45).
The heterodimerization between a prosurvival and a pro-
death member may be one of the most important mecha-
nisms in the regulation of apoptosis (15). A1 has been de-
scribed to interact with bax (46), which is a pro-death gene
expressed in mast cells (Fig. 2). Furthermore, bax has previ-
ously been suggested to be involved in the regulation of
mast cell apoptosis (47). Whether A1 acts as an antagonist
for bax in mast cells or if A1 promotes mast cell survival
through other mechanisms remains to be elucidated.
Both calcium ionophores, such as ionomycin, and com-
pound 48/80 are mast cell secretagogues which can effi-
ciently stimulate exocytosis. Ionomycin mimics Fc RI ag-
gregation signals by stimulating calcium influx. Our data
show that ionomycin stimulated A1 induction in a dose-
dependent manner (Fig. 5 A), which suggests that calcium
influx is required in the signaling pathways for A1 induc-
tion. The requirement for calcium mobilization has been
further substantiated by the fact that addition of EDTA
completely blocked A1 induction after Fc RI cross-link-
ing (Fig. 4). In contrast, compound 48/80 induces exocy-
tosis in a receptor-independent manner by interacting di-
rectly with heterotrimeric G proteins that are located
downstream of calcium mobilization (34). In our observa-
tions, although compound 48/80 could induce  -hex-
osaminidase release (Fig. 5 E), it failed to induce A1 tran-
script expression (Fig. 5 D) and the cells did not survive
(Fig. 5 F). Not surprisingly, compound 48/80 is used to
deprive mast cells in vivo (e.g., reference 48), and our
findings may explain the mechanisms by which mast cell
depletion is achieved.
We observed a strong inhibition of A1 expression after
treatment with dexamethasone (Fig. 4). Repression of nu-
clear factor (NF)- B–dependent gene expression is one of
the key characteristics by which glucocorticoids exert their
antiinflammatory effects. Recent studies show that the pro-
moter region of A1 contains NF- B binding sites, and sur-
vival mechanisms mediated by NF- B–dependent expres-
sion of A1 have been reported (49–51). When we take into
account these observations, it is tempting to speculate that
Fc RI-induced expression of A1 and mast cell survival is
mediated via NF- B, although this has yet to be proven.
It has been reported that TNF-  and GM-CSF can po-
tentiate A1 induction in macrophages and endothelial cells
(23, 26). We were therefore interested in characterizing
whether these or other cytokines were capable of upregu-
lating A1 transcript in mast cells. The cytokines that we
screened included the proinflammatory cytokines such as
TNF-  and GM-CSF, as well as cytokines that have
strong implications in the survival, differentiation, and
functional maintenance of mast cells such as SCF, NGF,
and IL-4 (18, 20, 36–38). The result indicated that none of
the cytokines tested could induce A1 induction. In a re-
cent publication by Yoshikawa et al. they described that
Fc RI-induced mast cell survival is mediated by autocrine
release of cytokines, i.e., IL-4 (52). In contrast to their
findings, we could not confirm that activation-induced
mast cell survival depends on factors released from the
cells. Supernatants from activated mast cells did not induce
A1 expression, but prevented apoptosis of cells that had
been deprived of growth factors probably because of the
presence of cytokines in the supernatant (unpublished
data). Furthermore, compound 48/80 did not induce A1
expression or mast cell survival, although it caused substan-
tial degranulation (Fig. 5). Taken together, these lines of
evidence would indicate that A1 induction in mast cells
may be a direct effect of Fc RI aggregation that requires
calcium influx as a prerequisite condition. Further studies
elucidating the regulation of A1 expression and function in
mast cells are currently in progress.
This study describes that Fc RI aggregation induces the
expression of A1 that is needed for mast cells to survive the
degranulation process during an allergic reaction. Recently
it was described that Fc RI aggregation also increases the
expression of Fas-associated death domain–like IL-1–con-
verting enzyme (FLICE), a protein involved in the protec-
tion against Fas-induced apoptosis (53). Although mast cells
express Fas and undergo apoptosis upon activation through
Fas (54), the physiological role for Fas–FasL interaction and
its importance for regulating mast cell number in vivo has1568 A1 Expression in Mast Cells
not been clarified. However, it appears that allergic activa-
tion by Fc RI aggregation can regulate mast cell survival
through different mechanisms.
Our finding that A1 plays a pivotal role in allergy-depen-
dent mast cell survival fits well with the characteristic of A1
as a pro-survival gene, acting rapidly upon activation. A di-
rect inhibition of A1 may prove beneficial in reducing mast
cell numbers in tissues affected by allergic reactions. The
challenge is now to determine whether A1 can be used as a
target for the development of new allergy therapies. It is
also possible that dysregulation of A1 in humans may in-
crease the susceptibility to mast cell–mediated disorders.
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